Literature DB >> 18982437

Conventional oral anticoagulation may not replace prior transesophageal echocardiography for the patients with planned catheter ablation for atrial fibrillation.

Hua He1, Junping Kang, Hailong Tao, Bin Zhen, Ming Zhang, Deyong Long, Jianzeng Dong.   

Abstract

INSTRUCTION: Preablation transesophageal echocardiography (TEE) is dispensable for the patients with planned catheter ablation for atrial fibrillation (AF) and having received at least a 3-week oral anticoagulation therapy according to the recommendations of the Venice Consensus. But the role of prior TEE and the effect of preablation short-term oral anticoagulation drugs (OACs) under the circumstance are still unclear. METHODS AND
RESULTS: A total of 188 patients with planned catheter ablation for AF and without previous long-term oral anticoagulation, whose duration of AF exceeded 48 h, were randomly divided into receiving 3-week OACs (OACs group) before heparin bridging or receiving no prior OACs (N-OACs group). Follow-up was performed until a TEE had been performed on all the cases before ablation. Consequently, the prevalence of atrial thrombi is 6.3% and 11.7%, respectively (P < 0.05), and the prevalence of minor bleeding is 5.3% and 0%, respectively (P < 0.05), in OACs and N-OACs group. There was no thrombotic event, major hemorrhage, in both groups.
CONCLUSION: After a 3-week effective oral anticoagulation, atrial thrombi could be resolved partly but not completely in the patients with AF who had not received long-term oral anticoagulation previously. To ensure safety, prior TEE may be necessary for the patients with planned catheter ablation for AF.

Entities:  

Mesh:

Year:  2008        PMID: 18982437     DOI: 10.1007/s10840-008-9322-2

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  31 in total

1.  Circumferential pulmonary-vein ablation for chronic atrial fibrillation.

Authors:  Hakan Oral; Carlo Pappone; Aman Chugh; Eric Good; Frank Bogun; Frank Pelosi; Eric R Bates; Michael H Lehmann; Gabriele Vicedomini; Giuseppe Augello; Eustachio Agricola; Simone Sala; Vincenzo Santinelli; Fred Morady
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

2.  Two-sided confidence intervals for the single proportion: comparison of seven methods.

Authors:  R G Newcombe
Journal:  Stat Med       Date:  1998-04-30       Impact factor: 2.373

3.  Efficacy of anticoagulation in resolving left atrial and left atrial appendage thrombi: A transesophageal echocardiographic study.

Authors:  W A Jaber; D L Prior; M Thamilarasan; R A Grimm; J D Thomas; A L Klein; C R Asher
Journal:  Am Heart J       Date:  2000-07       Impact factor: 4.749

4.  Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy.

Authors:  G Palareti; N Leali; S Coccheri; M Poggi; C Manotti; A D'Angelo; V Pengo; N Erba; M Moia; N Ciavarella; G Devoto; M Berrettini; S Musolesi
Journal:  Lancet       Date:  1996-08-17       Impact factor: 79.321

5.  Achievement of pulmonary vein isolation in patients undergoing circumferential pulmonary vein ablation: a randomized comparison between two different isolation approaches.

Authors:  Xingpeng Liu; Jianzeng Dong; Hercules E Mavrakis; Fuli Hu; Deyong Long; Dongping Fang; Ronghui Yu; Ribo Tang; Peng Hao; Chunshan Lu; Xiaokui He; Xiaohui Liu; Panos E Vardas; Changsheng Ma
Journal:  J Cardiovasc Electrophysiol       Date:  2006-12

6.  [The efficiency and safety of anticoagulation therapy in atrial fibrillation in Chinese].

Authors:  Yi-hong Sun; Da-yi Hu
Journal:  Zhonghua Nei Ke Za Zhi       Date:  2004-04

7.  Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study.

Authors:  Carlo Pappone; Salvatore Rosanio; Giuseppe Augello; Giuseppe Gallus; Gabriele Vicedomini; Patrizio Mazzone; Simone Gulletta; Filippo Gugliotta; Alessia Pappone; Vincenzo Santinelli; Valter Tortoriello; Simone Sala; Alberto Zangrillo; Giuseppe Crescenzi; Stefano Benussi; Ottavio Alfieri
Journal:  J Am Coll Cardiol       Date:  2003-07-16       Impact factor: 24.094

8.  Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4.5-year study.

Authors:  W J Manning; D I Silverman; C S Keighley; P Oettgen; P S Douglas
Journal:  J Am Coll Cardiol       Date:  1995-05       Impact factor: 24.094

9.  Atrial thrombi resolution after prolonged anticoagulation in patients with atrial fibrillation.

Authors:  G Corrado; G Tadeo; S Beretta; L M Tagliagambe; G F Manzillo; M Spata; M Santarone
Journal:  Chest       Date:  1999-01       Impact factor: 9.410

10.  Economic analysis of a transesophageal echocardiography-guided approach to cardioversion of patients with atrial fibrillation: the ACUTE economic data at eight weeks.

Authors:  Allan L Klein; R Daniel Murray; Edmund R Becker; Steven D Culler; William S Weintraub; Susan E Jasper; Elizabeth A Lieber; Carolyn Apperson-Hansen; Adrienne M Heerey; Richard A Grimm
Journal:  J Am Coll Cardiol       Date:  2004-04-07       Impact factor: 24.094

View more
  3 in total

Review 1.  Peri-procedural anticoagulation in patients undergoing ablation for atrial fibrillation.

Authors:  Sara R Vazquez; Stacy A Johnson; Matthew T Rondina
Journal:  Thromb Res       Date:  2010-01-06       Impact factor: 3.944

2.  Periprocedural management of anticoagulation and antiplatelet therapies in patients undergoing electrophysiologic procedures.

Authors:  Jordana Kron; Daniel Alexander; Mark A Wood
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-10

Review 3.  Left Atrium and Left Atrial Appendage Screening Prior to Atrial Fibrillation Ablation: A Comprehensive Review of the Literature.

Authors:  Nicholas J Serafini; Kousik Krishnan
Journal:  J Innov Card Rhythm Manag       Date:  2018-05-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.